TY - JOUR
T1 - Analysis of metabolites and metabolic pathways in breast cancer in a Korean prospective cohort
T2 - the Korean Cancer Prevention Study-II
AU - Yoo, Hye Jin
AU - Kim, Minjoo
AU - Kim, Minkyung
AU - Kang, Minsik
AU - Jung, Keum Ji
AU - Hwang, Se mi
AU - Jee, Sun Ha
AU - Lee, Jong Ho
N1 - Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - Introduction: Since blood is in contact with all tissues in the body and is considered to dynamically reflect the body’s pathophysiological status, serum metabolomics changes are important and have diagnostic value in early cancer detection. Objectives: In this prospective study, we investigated the application of metabolomics to differentiate subjects with incident breast cancer (BC) from subjects who remained free of cancer during a mean follow-up period of 7 years with the aim of identifying valuable biomarkers for BC. Methods: Baseline serum samples from 84 female subjects with incident BC (BC group) and 88 cancer-free female subjects (control group) were used. Metabolic alterations associated with BC were investigated via metabolomics analysis of the baseline serum samples using ultra-performance liquid chromatography-linear-trap quadrupole-Orbitrap mass spectrometry. Results: A total of 57 metabolites were identified through the metabolic analysis. Among them, 20 metabolite levels were significantly higher and 22 metabolite levels were significantly lower in the BC group than in the control group at baseline. Ten metabolic pathways, including amino acid metabolism, arachidonic acid (AA) metabolism, fatty acid metabolism, linoleic acid metabolism, and retinol metabolism, showed significant differences between the BC group and the control group. Logistic regression revealed that the incidence of BC was affected by leucine, AA, prostaglandin (PG)J 2 , PGE 2 , and γ-linolenic acid (GLA). Conclusions: This prospective study showed the clinical relevance of dysregulation of various metabolisms on the incidence of BC. Additionally, leucine, AA, PGJ 2 , PGE 2 , and GLA were identified as independent variables affecting the incidence of BC.
AB - Introduction: Since blood is in contact with all tissues in the body and is considered to dynamically reflect the body’s pathophysiological status, serum metabolomics changes are important and have diagnostic value in early cancer detection. Objectives: In this prospective study, we investigated the application of metabolomics to differentiate subjects with incident breast cancer (BC) from subjects who remained free of cancer during a mean follow-up period of 7 years with the aim of identifying valuable biomarkers for BC. Methods: Baseline serum samples from 84 female subjects with incident BC (BC group) and 88 cancer-free female subjects (control group) were used. Metabolic alterations associated with BC were investigated via metabolomics analysis of the baseline serum samples using ultra-performance liquid chromatography-linear-trap quadrupole-Orbitrap mass spectrometry. Results: A total of 57 metabolites were identified through the metabolic analysis. Among them, 20 metabolite levels were significantly higher and 22 metabolite levels were significantly lower in the BC group than in the control group at baseline. Ten metabolic pathways, including amino acid metabolism, arachidonic acid (AA) metabolism, fatty acid metabolism, linoleic acid metabolism, and retinol metabolism, showed significant differences between the BC group and the control group. Logistic regression revealed that the incidence of BC was affected by leucine, AA, prostaglandin (PG)J 2 , PGE 2 , and γ-linolenic acid (GLA). Conclusions: This prospective study showed the clinical relevance of dysregulation of various metabolisms on the incidence of BC. Additionally, leucine, AA, PGJ 2 , PGE 2 , and GLA were identified as independent variables affecting the incidence of BC.
KW - Breast cancer
KW - Cohort
KW - Early biomarkers
KW - Metabolites
KW - Metabolomics
KW - Prospective study
UR - http://www.scopus.com/inward/record.url?scp=85048464532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048464532&partnerID=8YFLogxK
U2 - 10.1007/s11306-018-1382-4
DO - 10.1007/s11306-018-1382-4
M3 - Article
C2 - 30830383
AN - SCOPUS:85048464532
SN - 1573-3882
VL - 14
JO - Metabolomics
JF - Metabolomics
IS - 6
M1 - 85
ER -
